Let’s go! I don’t stream many tv shows these days- but excited for this one.. Believe!

Let’s go Heels!

After nine years at William Blair, I’ve decided to leave the firm for a new opportunity. I will cherish my time there and have developed lifelong friendships along the way. Excited for the next step in my journey. Stay tuned for an update next week!

Excited to join CRISPR Therapeutics !

One of many reasons why I joined CRISPR Therapeutics !

We are pleased to share that we have entered into a new non-exclusive licensing agreement with Vertex for the use of CRISPR Therapeutics's gene editing technology to accelerate development of Vertex’s hypoimmune cell therapies for type-1 diabetes (T1D). Read more: bit.ly/42ULcHM

Excited to be joining for this great cause! Donate here: justgiving.com/fundraising/Ra…

The submission of these BLAs represents an exciting moment for the field of gene editing and future of CRISPR-based treatments. I’m proud to be working alongside the teams who made this achievement possible.

Today, we announced preclinical data from our investigational programs for the treatment of cardiovascular disease at the American Heart Association (AHA) Scientific Sessions 2023. Learn more here bit.ly/47oCkLX #AHA23

Join Boston CEO this October as top #biopharma executives convene at Mandarin Oriental for top tier networking, discussions & fireside chats. longwoodhealthcareleaders.com/bostonceo

We’re proud to share that we’ve been named on the TIME Best Inventions of 2024 list! This list recognizes a wide variety of new products, software or services that are making a difference in the world. #TIMEBestInventions

Pleased to share positive news coming out of our Q1 2025 earnings, including top-line data from our Phase 1 clinical trial of CTX310™ targeting ANGPTL3. Congratulations to the team!

Today, we announced a collaboration with Sirius Tx to co-develop SRSD107, a next generation, long-acting Factor XI siRNA for the treatment of thromboembolic disorders. This will expand our cardiovascular portfolio and broaden our therapeutic toolkit. bit.ly/4kjPEaS

We're excited to announce our partnership with Sirius Therapeutics! This collaboration strengthens our gene-based therapy pipeline, aiming to address unmet medical needs and create long-term value for patients, partners, and shareholders.

Honored that CRISPR Therapeutics is on the TIME 2025 Most Influential Companies list. A reflection of our work to deliver meaningful breakthroughs for patients. #CRISPRTX #TIME100Companies #Biotech

We’re excited to announce the acceptance of two late-breaking data presentations at the upcoming American Heart Association (AHA) Scientific Sessions 2025, taking place November 7-10 in New Orleans. Learn more here: bit.ly/3KdhloQ AHA Science #AHA25

Today, we announced with Sirius Tx that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a next-generation, long-acting Factor XI siRNA for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty: bit.ly/3KeXd5Z